Biosimilar Antibodies

Vobramitamab is a humanized monoclonal antibody targeting B7-H3, conjugated to the prodrug seco-DUBA through a cleavable linker to create the antibody-drug conjugate (ADC) MGC018. This ADC has demonstrated potent antitumor efficacy in preclinical models across a variety of cancers, including breast, ovarian, lung cancer, and melanoma. MGC018's design allows for targeted delivery of the cytotoxic agent to tumor cells, minimizing systemic exposure and enhancing therapeutic potential.

Crebankitug is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets the IL7 receptor (IL7R). For experimental control purposes, it is recommended to use Human IgG1 lambda2 as an isotype control. This antibody is designed for use in research studies to investigate IL7R-mediated signaling pathways and potential therapeutic applications targeting IL7R.

The Anti-CHI3L1 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CHI3L1. This antibody is comprised of a human IgG1 type heavy chain and a human kappa-type light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended as the isotype control for this antibody. This product is essential for researchers focusing on the biological pathways and disease associations involving CHI3L1.

Pulocimab is a monoclonal antibody targeting VEGFR2 (vascular endothelial growth factor receptor 2), designed for use in cancer research. This antibody binds specifically to VEGFR2, inhibiting its signaling pathways, which are critical for tumor angiogenesis and growth. Pulocimab offers a valuable tool for researchers studying the molecular mechanisms of cancer progression and exploring potential therapeutic strategies targeting angiogenesis.

Vipalanebart is a human IgG4 κ monoclonal antibody targeting ADCYAP1R. For optimal experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody provides a valuable tool for the specific detection and characterization of ADCYAP1R in various research applications.

Blinatumomab, also known as Anatumomab, is a bispecific monoclonal antibody designed to simultaneously engage two distinct epitopes: CD3E on T cells and CD19 on B cells. This unique dual-binding capability facilitates the redirection of T cells to target and eliminate CD19-expressing B cells. Blinatumomab is primarily utilized in research focused on the treatment and understanding of acute lymphoblastic leukemia (ALL), offering significant insights into therapeutic strategies and disease management.

Gavilimomab (ABX-CBL) is an IgM murine monoclonal antibody designed to target CD147, a cell surface antigen. This antibody facilitates cell death via complement-mediated lysis. It is primarily utilized in the study of graft-versus-host disease (GVHD), offering a valuable tool for researchers investigating the pathophysiology and potential therapeutic interventions of this condition.

AGS-67E is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting TSPAN26/CD37. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 143.44 kDa. For experimental control purposes, Human IgG2 kappa, Isotype Control is recommended. AGS-67E is applicable for a range of research studies focusing on the biological functions and therapeutic targeting of TSPAN26/CD37.

The Anti-EphA2 Antibody (1C1), also known as MEDI-547, is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the EphA2 receptor, a critical component involved in various cellular processes including angiogenesis, neurogenesis, and cancer progression. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, and has a predicted molecular weight of 146.68 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Pavurutamab (AMG-701) is a bispecific T-cell engager that targets both CD3 on T-cells and B-cell maturation antigens (BCMA) on plasma cells. This molecule is engineered with an extended half-life derivative of Pacanalotamab, enhancing its stability and duration of action. The Fc region of Pavurutamab has been modified to incorporate molecules that optimize its pharmacokinetic properties, ensuring sustained efficacy. This biologic is primarily investigated for its potential therapeutic applications in the modulation of immune responses and as a treatment for multiple myeloma (MM).

Ponsegromab (PF 06946860) is a potent, selective humanized monoclonal antibody targeting GDF15, designed to inhibit its interaction with the GFRAL receptor. By binding to GDF15, Ponsegromab effectively prevents GDF15 from engaging with the GFRAL receptor, thereby obstructing the GDF15/GFRAL-mediated signaling pathway. This antibody exhibits significant anti-cachexia activity, making it a valuable tool for research in oncology settings where cachexia is prevalent.

Mirvetuximab (M9346A) is a monoclonal antibody targeting FOLR1 (folate receptor 1), specifically designed to bind to folate receptor alpha (FRα). This antibody serves as the crucial component of the antibody-drug conjugate (ADC) Mirvetuximab soravtansine, which is utilized in the investigation of ovarian and other FRα-positive cancers. Mirvetuximab soravtansine's mechanism focuses on delivering cytotoxic agents directly to cancer cells expressing FRα, thereby enhancing therapeutic efficacy while minimizing off-target effects. This product is essential for research aimed at developing targeted therapies for FRα-expressing tumors.

Carotuximab (TRC105) is an IgG1 monoclonal antibody designed to inhibit endoglin (CD105), a critical component of the Smad signaling pathway. This antibody exhibits both immunomodulatory and antineoplastic properties, making it a valuable tool in cancer research and therapy development. Carotuximab targets endoglin-expressing cells, thereby interfering with cellular processes essential for tumor growth and angiogenesis.

Patecibart is a humanized IgG4-kappa monoclonal antibody designed to specifically target and inhibit the endothelin receptor type A (EDNRA). As an endothelin receptor antagonist, it plays a critical role in modulating vascular function by blocking the binding of endothelin-1 to its receptor, potentially alleviating conditions associated with vascular dysfunction and constriction. This antibody is pivotal for research focused on cardiovascular diseases, pulmonary arterial hypertension, and other endothelin-related pathologies.

Gocatamig is a chimeric humanized antibody designed with a single-chain variable fragment-heavy-lambda (scFv-heavy-lambda)-VH-VH' configuration. It specifically targets CD3E, ALB, and DLL3, making it suitable for advanced research applications that investigate cellular processes involving these proteins. This antibody's unique structure and specificity are ideal for studies in immunology and oncology, particularly in the modulation of immune responses and the investigation of cancer cell dynamics.

The Anti-TNFSF2/TNFa Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets TNFSF2/TNFa, a pivotal cytokine involved in systemic inflammation and the acute phase response. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, it is recommended to use the Human IgG1 kappa, Isotype Control. This antibody is suitable for a range of research applications, providing a critical tool for the study of TNF-alpha's role in disease pathogenesis and therapeutic interventions.

ATG-031 is a humanized monoclonal antibody targeting CD24, designed to enhance the immune system's ability to combat cancer. By inhibiting CD24-mediated "don't eat me" signals, ATG-031 promotes macrophage-mediated phagocytosis, leading to the destruction of cancer cells. This antibody is applicable in research focused on both hematological malignancies and solid tumors, providing a valuable tool for studies aimed at understanding and potentially disrupting cancer cell survival mechanisms.

PF-07062119 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to specifically target and inhibit guanylate cyclase 2C (GUCY2C). For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This product is essential for research focused on the role of GUCY2C in various biological processes and disease states.

Dectrekumab (QAX576) is a human monoclonal antibody designed to selectively target interleukin-13 (IL-13). This antibody has demonstrated efficacy in significantly reducing intraepithelial esophageal eosinophil counts and normalizing dysregulated disease-related transcripts in patients with Eosinophilic Esophagitis (EoE). Its sustained activity makes it an invaluable tool for research focused on inflammation and immunological disorders.

ALT-836 is a recombinant chimeric monoclonal antibody of the IgG4κ subclass that specifically targets human tissue factor (TF) and the TF-FVIIa complex. By binding to these entities, ALT-836 effectively prevents the association and subsequent activation of Factor X (FX), thereby inhibiting the generation of thrombin. This mechanism plays a crucial role in modulating thrombotic processes, making ALT-836 an essential tool for research in coagulation and cardiovascular disorders.

CTX-471 is a fully human monoclonal antibody targeting CD137, a receptor involved in the regulation of immune responses. This antibody demonstrates high binding affinity to recombinant CD137 from various species, with dissociation constants (Kd) of 50 nM for human, 61 nM for cynomolgus macaque, and 748 nM for mouse CD137. CTX-471 is primarily utilized in research focused on immunomodulation and oncology, offering a valuable tool for studies aimed at understanding and manipulating immune pathways in cancer therapy.

Mipasetamab is an IgG1κ monoclonal antibody specifically designed to target AXL, a member of the TAM family of receptor tyrosine kinases. This antibody plays a crucial role in the synthesis of ADCT-601 (Mipasetamab uzoptirine), an antibody-drug conjugate (ADC) that selectively binds to the AXL receptor. ADCT-601 demonstrates significant antitumor activity, leveraging the specificity of Mipasetamab to deliver cytotoxic agents directly to AXL-expressing tumor cells, thereby enhancing therapeutic efficacy while minimizing off-target effects. This product is pivotal for research focused on the development of targeted cancer therapies, particularly in studies investigating the role of AXL in cancer progression and resistance mechanisms.

The Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is a humanized monoclonal antibody targeting LAMP1/CD107a. This antibody serves as the antibody component of the therapeutic SAR-428926. It is characterized as Human IgG1 kappa and can also be utilized as an isotype control in various experimental setups. This product is designed for research applications, focusing on the study of lysosomal associated membrane protein 1 (LAMP1), which is critical in cellular processes such as autophagy and lysosome stabilization.

Gantenerumab is a fully humanized IgG1 monoclonal antibody designed to target amyloid-beta (Aβ) fibrils and plaques, which are hallmark features in the pathology of Alzheimer's disease. This antibody exhibits high specificity for Aβ aggregates, making it an essential tool for research focused on the mechanisms and therapeutic interventions of Alzheimer's disease. Gantenerumab is particularly valuable in studies aiming to understand the role of amyloid plaques in neurodegeneration and as a potential therapeutic agent in clinical settings.

Torapsel (42-89-glycoprotein; WAY164339) is a fusion protein that incorporates elements of immunoglobulin. This biologic is specifically designed for use in experimental studies focused on the prevention of ischemia-reperfusion injury. Torapsel's unique structure and functional properties make it a valuable tool for researchers investigating cellular mechanisms and therapeutic interventions related to tissue damage following restored blood flow after ischemic events.

Crefmirlimab is a humanized minibody specifically targeting CD8. This minibody retains the target specificity characteristic of full-length antibodies while lacking immune effector functions, rendering it biologically inert. This feature makes it particularly suitable for detailed studies of CD8 interactions without eliciting an immune response, ideal for controlled experimental setups in immunology and oncology research.

Lexatumumab (HGS-ETR 2) is a human monoclonal antibody of the IgG4κ subtype that functions as an agonist to TRAIL receptor 2 (TRAIL-R2, also known as DR5 or APO-2). This antibody is specifically designed to induce apoptosis in cells exhibiting malignant mesothelioma characteristics. It is primarily utilized in research focused on understanding and treating malignant pleural mesothelioma (MPM), offering significant value in studies aimed at exploring targeted cancer therapies.

Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody engineered to specifically neutralize the alpha-toxin (alpha-hemolysin; Hla) produced by Staphylococcus aureus. By targeting an N-terminal epitope of alpha-toxin, Tosatoxumab inhibits the oligomerization process essential for the formation of functional toxin pores. This antibody offers promising applications in passive immunotherapy for Staphylococcus aureus pneumonia, serving as an adjunctive treatment alongside standard antibiotic therapies.

Atibuclimab is a chimeric monoclonal antibody targeting CD14, comprised of murine variable regions and human IgG4 Fc regions. This antibody is specifically designed for research purposes in amyotrophic lateral sclerosis (ALS). Atibuclimab effectively moderates lipopolysaccharide (LPS)-induced symptoms and robustly suppresses the release of proinflammatory cytokines induced by LPS. Concurrently, it moderately delays the secretion of anti-inflammatory cytokines, including soluble TNF receptor type I and IL-1 receptor antagonist, providing a distinct profile of cytokine regulation. This dual action makes Atibuclimab a valuable tool for investigating inflammatory pathways and their modulation in ALS research.

Rolistobart is a humanized monoclonal antibody of the immunoglobulin G4-kappa subtype, specifically targeting LILRB4/CD85k. It functions as both an immunostimulant and an antineoplastic agent, designed to modulate immune responses and inhibit tumor growth. This antibody is utilized primarily in the study of cancer immunotherapy, focusing on its potential to enhance immune system recognition and destruction of cancer cells.

Olintatug is a chimeric humanized antibody of the IgG1κ subtype that specifically targets KAAG1. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.

Maftivimab (REGN3470-3471-3479), also known as Atoltivimab and Odesivimab under the brand name Inmazeb, is an FDA-approved monoclonal antibody cocktail designed to inhibit Filovirus activity. This biologic is specifically targeted against the Zaire ebolavirus, making it highly relevant for research focused on this pathogen. Maftivimab is utilized in studies investigating the mechanisms of viral entry and replication, as well as in the development of therapeutic strategies for Ebola virus infection.

The Anti-IL-20 Antibody is a humanized monoclonal antibody produced in Chinese hamster ovary (CHO) cells, specifically designed to target IL-20. This antibody consists of a human IgG1 type heavy chain and a human kappa type light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Emerfetamab is a monoclonal antibody designed to target both CD3E and CD33 molecules. This dual specificity enables it to engage T cells via CD3E and simultaneously recognize myeloid cells through CD33, making it a valuable tool in the research of immune cell interactions and potential therapeutic applications in hematological malignancies.

Nezastomig is a human IgG4 κ monoclonal antibody targeting FOLH1/CD28. For accurate experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for specificity to FOLH1/CD28, making it suitable for a range of research applications investigating the role of this target in various biological processes.

Inebilizumab is a monoclonal antibody targeting CD19 with enhanced capabilities for antibody-dependent cell-mediated cytotoxicity (ADCC) directed against B cells. This antibody is utilized in research focused on multiple sclerosis and neuromyelitis optica, providing a valuable tool for studying disease mechanisms and potential therapeutic interventions in these conditions.

Navicixizumab (OMP-305B83) is a bispecific antibody designed to inhibit both vascular endothelial growth factor (VEGF) and Delta-like ligand 4 (DLL4). This dual inhibition mechanism makes it a potent candidate for use in oncology research, particularly in studies involving ovarian, primary peritoneal, or fallopian tube cancers. Navicixizumab has shown potential for use in combination with Paclitaxel, enhancing its applicability in therapeutic research protocols aimed at targeting cancer angiogenesis and tumor growth.

The Anti-CD2 Antibody (CB.219) is a chimeric mouse monoclonal antibody of the IgG2b, κ subclass, specifically designed to target human CD2. This antibody is ideal for research applications requiring precise CD2 modulation or detection. For accurate experimental control, it is recommended to use the Mouse IgG2b kappa, Isotype Control.

Nivolumab is a human IgG4 monoclonal antibody that inhibits the programmed death receptor-1 (PD-1) pathway, offering therapeutic benefits in the management of advanced (metastatic) non-small cell lung cancer. This antibody functions by blocking the interaction between PD-1 and its ligands, thereby enhancing the immune response against tumor cells. It is specifically designed for the treatment of patients with advanced stages of this malignancy, where it has shown efficacy in improving patient outcomes.

Dazukibart is a humanized IgG1κ monoclonal antibody derived from mouse sources, specifically designed to target Interferon beta 1 (IFNB1). This antibody is engineered to bind selectively to IFNB1, making it an essential tool for research focused on the role of this cytokine in immune response and inflammatory processes. Dazukibart is suitable for a variety of experimental applications, including functional assays and immunological studies aimed at elucidating the biological pathways mediated by IFNB1.

The Anti-Mesothelin Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets mesothelin, a protein frequently overexpressed in various forms of cancer, including mesothelioma and ovarian carcinoma. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and it has a predicted molecular weight of 150 kDa. For isotype control purposes, reference is made to the Human IgG1 kappa, Isotype Control. This antibody serves as a valuable tool for research focused on cancer biology and the therapeutic targeting of mesothelin-positive tumors.

Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody designed to specifically target and inhibit CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). By antagonizing the inhibitory checkpoints mediated by CTLA-4 signaling, Zalifrelimab enhances immune cell activation, potentially amplifying antitumor immune responses. This antibody is utilized in research focused on immunotherapy and the modulation of immune checkpoints in oncology.

Intetumumab (CNTO 95) is a glycoengineered anti-EGFR monoclonal antibody designed to enhance antibody-dependent cellular cytotoxicity (ADCC). This potent therapeutic tool is specifically utilized in cancer research to investigate the mechanisms of tumor cell inhibition mediated by EGFR targeting.

Varisacumab (R 84) is a monoclonal antibody designed for biochemical research applications. This antibody offers specificity in targeting and studying molecular interactions, making it a valuable tool for a wide range of biochemical investigations.

Visilizumab is a humanized monoclonal IgG2 antibody with low Fc receptor binding affinity, targeting CD3E. This recombinant antibody is designed for the study of immune-mediated gastrointestinal disorders, including ulcerative colitis and Crohn's disease. Its specificity for CD3E makes it a valuable tool in research focused on T-cell mediated responses in these conditions.

Edrecolomab (Panorex) is a murine monoclonal antibody that targets the cell-surface glycoprotein 17-1A, which is expressed on epithelial tissues and various carcinomas. This antibody exhibits anti-tumor activity, making it particularly useful in the study of colorectal carcinoma.

Ranevetmab (NV-01) is a caninized monoclonal antibody targeting nerve growth factor (NGF). This antibody is specifically engineered for use in canine models to investigate and alleviate pain associated with degenerative joint disease (DJD). Ranevetmab binds selectively to NGF, a key mediator in the pathway of pain, thereby inhibiting its activity and providing a valuable tool for research into novel pain therapies in veterinary medicine.

Flanvotumab (IMC-20D7S) is a human monoclonal antibody designed to specifically target tyrosinase-related protein 1 (TYRP1), which is predominantly expressed in melanocytes and melanoma cells. This antibody mediates its effects through the mechanism of antibody-dependent cell-mediated cytotoxicity (ADCC), engaging the body's natural killer cells to destroy tumor cells. Flanvotumab demonstrates significant anti-tumor activity and is well-tolerated, making it a valuable tool for research in melanoma therapeutics.

Emicizumab is a bispecific monoclonal antibody designed to mimic the function of activated factor VIII by bridging activated factor IX and factor X, effectively restoring hemostasis. This antibody is utilized primarily in research focused on hemophilia A, offering a novel approach to studying and potentially managing this bleeding disorder.

Ozanezumab (GSK1223249) is a monoclonal antibody targeting Nogo-A, a protein known to inhibit neurite outgrowth. This antibody is primarily utilized in the study of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), providing a valuable tool for exploring the mechanisms underlying these diseases and potential therapeutic approaches.